H1

MedTech kicks off next week! H1’s Chris Gardella, SVP Commercial and Kyle Horton, Account Executive will be at #MTC24 to support medical device companies as they prepare to meet FDA guidance on Diversity Action Plans. Want to see how other med device companies are using H1 to support FDA diversity planning? Connect with Chris and Kyle to see how H1 empowers medical device sponsors to find diverse sites and patients for more equitable clinical trials. Hope to see you there! https://hubs.la/Q02Sx-wn0 #medtech #healthequity #clinicaltrialdiversity #equitablecare #healthcareinnovation

As the scope of Medical Affairs continues to evolve, so does the need to be able to effectively measure the impact of their outreach efforts. Traditional measurements of pharma success, like sales and script volumes, are not things MSLs directly influence. While some subjective measurements can be made related to activity metrics and advocacy scoring, these metrics miss the full picture of Medical Affairs contributions – which should include not only quantity but quality of interactions, including influence on clinical practices. Learn more: https://hubs.la/Q02Sl7Ws0

Bristol Myers Squibb has received a momentous approval from the FDA for a new antipsychotic drug to treat patients with schizophrenia. Unlike available antipsychotics that work to balance dopamine or serotonin levels, Cobenfy activates “muscarinic receptors” to harmonize certain brain circuits. While there are concerns about adoption and insurance coverage, clinical trials showed that the drug significantly relieved schizophrenia symptoms without some of the side effects common to other antipsychotics. Learn more: https://hubs.la/Q02RFGny0 #schizophrenia #bms #bristolmyerssquibb #antipsychotics #mentalhealth

Find out how clinical trial sponsors are preparing to follow the new FDA guidance on diversity action plans and how technology solutions can support this effort. Our 2024 report into the State of Diversity and Equity in Clinical Trials identifies the latest developments and strategic insights that are critical for enhancing clinical trial diversity. Download here: https://hubs.la/Q02S24L10 #healthequity #clinicaltrialdiversity #patientrepresentation #diversityinclusion

In times of crisis, mobilizing resources efficiently can be the difference between life and death. Technology offers a powerful tool to cut through the red tape to focus on what truly matters—saving lives. In his new article for Forbes Technology Council, our CEO Ariel Katz highlights how harnessing innovative technologies can be pivotal to transcending the limitations of politics and policy during times of need. Read more here: https://hubs.la/Q02RTswm0 #HumanitarianEfforts #MedicalAid

Will you be attending The MedTech Conference in a couple of weeks? H1’s Chris Gardella, SVP Commercial and Kyle Horton, Account Executive will be at #MTC24 to support medical device companies as they prepare to meet FDA guidance on Diversity Action Plans. Would it benefit you to see how other med device companies are using H1 to support FDA diversity planning? Connect with Chris and Kyle to see how H1 empowers medical device sponsors to find diverse sites and patients for more equitable clinical trials. Hope to see you there! https://hubs.la/Q02RJlfQ0 #medtech #healthequity #clinicaltrialdiversity #equitablecare #healthcareinnovation

While many eyes have been focused on the FDA's latest draft guidance for Diversity Action Plans, global diversity regulations are also evolving. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is set to release new diversity and inclusion guidelines later this year to improve care for underserved populations. Improving clinical trial representation depends on finding the right trial sites for your studies. H1 offers diversity insights in England that inform and strengthen equitable clinical trial planning. Learn more about how Trial Landscape can support global efforts to build more diverse clinical trials: https://hubs.la/Q02Rx_Yq0 Request a demo here: https://hubs.la/Q02RyclN0 #diversityinclusion #d&i #clinicaltrialdiversity #healthequity #patientdiversity

Later this week, the 2024 Innovation Network Gathering will ask participants to identify the biggest barriers to designing more human-centric clinical trials and to begin developing solutions to help shape a more patient-centered future. H1’s Ryan B., Regional VP of Sales, will be attending to help solve the most pressing challenges of clinical trials and to explore the potential impact of new technologies like AI on clinical research. Learn more: https://hubs.la/Q02Rjtcq0 #innovationnetworkgathering #humancentrictrials #clinicaltrialdiversity #healthequity #healthcareinnovation

We appreciate the excellent turnout for this morning's panel at #FierceClinicalSummit about “Paving the Way for Innovation.” Our CEO & Co-founder Ariel Katz joined an incredible group of experts for a thoughtful conversation about novel strategies that are impacting clinical efficiency and quality. The H1 team will be at booth 6 for the remainder of the conference if you have follow-up questions or would like to see our solutions in action. Hope to speak with you! #healthcareinnovation #clinicaltrials #ai #clinicalinsights

UCB is celebrating 3 FDA approvals this week for its IL-17A and IL-17F inhibitor drug Bimzelx. UCB states that it is now the only treatment of its kind to be approved in the U.S. for four chronic immune-mediated inflammatory diseases. The approvals came following four phase 3 trials that showed the drug delivered better results when compared to placebo in improving symptoms of the inflammatory diseases. Learn more: https://hubs.la/Q02QWvtJ0 #ucb #bimzelx #inflammatorydisease